Use of tigecycline for the management of Clostridium difficile colitis in oncology patients and case series of breakthrough infections
Authors:
- 1 April 2017
- journal article
- Published by Elsevier in Journal of Hospital Infection
- Vol. 95 (4) , 426-432
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile InfectionAntimicrobial Agents and Chemotherapy, 2014
- Clostridium difficileColitis: A ReviewHospital Practice, 2012
- Fidaxomicin versus Vancomycin forClostridium difficileInfectionNew England Journal of Medicine, 2011
- Recent epidemiology of Clostridium difficile infection during hematopoietic stem cell transplantationClinical Transplantation, 2010
- Clostridium difficileinfection in cancer patients and hematopoietic stem cell transplant recipientsExpert Review of Anti-infective Therapy, 2010
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)Infection Control & Hospital Epidemiology, 2010
- Activity of tigecycline against recent European clinical isolates of Clostridium difficileInternational Journal of Antimicrobial Agents, 2010
- Fulminant Clostridium difficile colitisCurrent Opinion in Critical Care, 2007
- Narrative Review: The New Epidemic of Clostridium difficile–Associated Enteric DiseaseAnnals of Internal Medicine, 2006
- Effect of Tigecycline on Normal Oropharyngeal and Intestinal MicrofloraAntimicrobial Agents and Chemotherapy, 2006